Contravisory Investment Management Inc. Invests $1.02 Million in DaVita Inc. $DVA

Contravisory Investment Management Inc. acquired a new stake in DaVita Inc. (NYSE:DVA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,610 shares of the company’s stock, valued at approximately $1,016,000.

Other large investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after buying an additional 636,191 shares in the last quarter. Norges Bank acquired a new position in shares of DaVita in the fourth quarter worth $49,164,000. Corient Private Wealth LLC grew its stake in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after acquiring an additional 335,809 shares in the last quarter. Man Group plc increased its position in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares during the period. Finally, Neuberger Berman Group LLC raised its stake in shares of DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after acquiring an additional 269,015 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on DVA. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their target price for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Barclays boosted their price objective on DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Finally, UBS Group upped their target price on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $199.17.

DaVita Trading Up 0.1%

Shares of DVA stock opened at $213.31 on Friday. The company has a market cap of $13.69 billion, a P/E ratio of 19.79, a PEG ratio of 0.70 and a beta of 0.91. The firm has a fifty day moving average price of $187.13 and a 200 day moving average price of $152.04. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $215.33.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the firm earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts forecast that DaVita Inc. will post 15.07 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.